2025-10-20 - Analysis Report
Okay, here's an analysis of Tempus AI Inc. (TEM) based on the information provided, presented in a clear and concise manner with numerical data first, followed by analysis.

**Report on Tempus AI Inc. (TEM)**

**0. Overview**

*   Ticker: TEM
*   Company: Tempus AI Inc.
*   Description: Tempus AI is a technology company advancing precision medicine through data and artificial intelligence.

**1. Performance Analysis**

*   **Cumulative Returns:**
    *   TEM: 44.21%
    *   S&P 500 (VOO): 26.28%
    *   Difference: 17.93%
*   **Relative Outperformance:** Current Relative Divergence: 50.9 (on a scale where min/max divergence from the comparison stock represents 0/100)

**Analysis:** TEM has significantly outperformed the S&P 500 based on cumulative returns. A relative outperformance level of 50.9 indicates this difference is currently in the middle of its recent historical range.

*   **Alpha, Beta Analysis:**

    | Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
    |------------|-------|-------|-------|------|--------|
    | 2023-2025  | 44.0% | 77.2% | 19.0% | 0.3  | 15.2   |

**Analysis:** The CAGR is very high, but so is the MDD(Maximum Drawdown), which is the maximum loss from peak to trough. The Alpha is also very high, but the Beta is low.

**2. Recent Price Action**

*   **Price:** 87.78
*   **Previous Close:** 91.02
*   **Change:** -3.56
*   **Moving Averages:**
    *   5-day: 91.01
    *   20-day: 88.49
    *   60-day: 77.90

**Analysis:** The stock price decreased by -3.56 in the most recent session. The price is below the 5-day and 20-day moving averages, but above the 60-day moving average, suggesting a possible short-term downward trend.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment)
*   **RSI:** 59.68 (Neutral)
*   **PPO:** -0.97 (Bearish)
*   **Hybrid Signal:** Cash_79%_Sell (Risky - MRI:0.50)
*   **Delta Relative Divergence (20-day):** -11.7 (Negative - indicating short-term decline in relative performance vs VOO)
*   **Expected Return:** NaN %

**Analysis:** The Market Risk Indicator suggests low investment, while the RSI is neutral. The PPO is slightly bearish, and the hybrid signal recommends a significant cash position and selling holdings. The negative change in relative divergence confirms recent underperformance compared to the S&P 500. The NaN expected return may indicate insufficient data for the AI to calculate that metric. The recent price change of -3.56 suggests a possible short-term downward trend.

**4. Recent News & Significant Events**

*   **Collaborations:** Partnerships with Whitehawk Therapeutics to advance oncology research (Oct 16, 2025).
*   **Conference Presentations:** Six abstracts accepted at the European Society for Medical Oncology Congress 2025 (Oct 15, 2025).
*   **Government Program:** Selected by ARPA-H for the ADAPT program, advancing precision cancer therapy (Oct 9, 2025).
*   **Positive Coverage:** Bull case theory highlighted by Insider Monkey (Oct 8, 2025).

**Analysis:** Recent news is overwhelmingly positive, highlighting collaborations, conference participation, government contracts, and positive media coverage. This suggests strong business momentum.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.15)
*   **Opinions:** 11 Analysts
*   **Target Price:**
    *   Average: 77.55
    *   High: 100.00
    *   Low: 60.00
*   **Recent Rating Changes:** No changes listed.

**Analysis:** Analyst consensus is generally positive ("Buy"). However, the average target price is lower than the current price, implying a potential overvaluation by the market.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 예상 EPS |
|------------|-------|----------|
| 2025-08-08 | -0.22 | -0.22988 |
| 2025-05-06 | -0.24 | -0.26003 |
| 2025-02-24 | -0.18 | -0.15    |
| 2024-11-04 | -0.25 | -0.26608 |
| 2024-08-06 | -0.63 | -0.59    |

**Analysis:** TEM has not yet achieved profitability, with all reported EPS figures being negative.  However, in most recent quarters, the actual EPS has either beaten or met expectations.

**6. Financial Information**

**Revenue and Profitability**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.31B   | 61.99%       |
| 2025-03-31 | $0.26B   | 60.69%       |
| 2024-12-31 | $0.20B   | 60.83%       |
| 2024-09-30 | $0.18B   | 58.50%       |
| 2024-06-30 | $0.17B   | 45.50%       |

**Capital and Profitability**

| Quarter    | Equity   | ROE        |
|------------|----------|------------|
| 2025-06-30 | $0.31B   | -13.84%    |
| 2025-03-31 | $0.33B   | -20.86%    |
| 2024-12-31 | $0.06B   | -23.10%    |
| 2024-09-30 | $0.05B   | -141.16%   |
| 2024-06-30 | $0.10B   | -562.04%   |

**Analysis:** Revenue is growing consistently, and profit margins are strong and expanding. However, the company currently has negative Return on Equity (ROE), reflecting the lack of profitability despite increasing revenue.

**7. Overall Assessment**

Tempus AI (TEM) presents a mixed picture.

*   **Positives:**
    *   Significant outperformance vs. S&P 500 historically.
    *   Strong revenue growth and high profit margins.
    *   Positive news flow regarding collaborations and advancements in cancer research.
    *   Favorable analyst consensus ("Buy").
*   **Negatives:**
    *   Not yet profitable, with negative EPS and ROE.
    *   High Maximum Drawdown.
    *   Short-term underperformance relative to the S&P 500, indicated by recent price action and relative divergence.
    *   Average analyst target price is lower than the current price.

**Conclusion:** TEM is a high-growth company with promising technology and strong industry tailwinds. However, investors should be aware of the risks associated with its lack of current profitability, high valuation, and recent short-term underperformance. The hybrid signal is indicating a cash position, perhaps as a defense against volatility.
